89 related articles for article (PubMed ID: 8654689)
1. Specificity of integrin I-domain-ligand binding.
Calderwood DA; Tuckwell DS; Humphries MJ
Biochem Soc Trans; 1995 Nov; 23(4):504S. PubMed ID: 8654689
[No Abstract] [Full Text] [Related]
2. Monoclonal antibodies identify residues 199-216 of the integrin alpha2 vWFA domain as a functionally important region within alpha2beta1.
Tuckwell DS; Smith L; Korda M; Askari JA; Santoso S; Barnes MJ; Farndale RW; Humphries MJ
Biochem J; 2000 Sep; 350 Pt 2(Pt 2):485-93. PubMed ID: 10947963
[TBL] [Abstract][Full Text] [Related]
3. Fine mapping of inhibitory anti-alpha5 monoclonal antibody epitopes that differentially affect integrin-ligand binding.
Burrows L; Clark K; Mould AP; Humphries MJ
Biochem J; 1999 Dec; 344 Pt 2(Pt 2):527-33. PubMed ID: 10567237
[TBL] [Abstract][Full Text] [Related]
4. Divalent cations stabilize the alpha 1 beta 1 integrin I domain.
Gotwals PJ; Chi-Rosso G; Ryan ST; Sizing I; Zafari M; Benjamin C; Singh J; Venyaminov SY; Pepinsky RB; Koteliansky V
Biochemistry; 1999 Jun; 38(26):8280-8. PubMed ID: 10387073
[TBL] [Abstract][Full Text] [Related]
5. Role of the I-domain in collagen binding specificity and activation of the integrins alpha1beta1 and alpha2beta1.
Kern A; Marcantonio EE
J Cell Physiol; 1998 Sep; 176(3):634-41. PubMed ID: 9699516
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of fibrinogen binding to the domain of CD11c, an alpha subunit of p150,95.
Nham SU
Biochem Biophys Res Commun; 1999 Nov; 264(3):630-4. PubMed ID: 10543983
[TBL] [Abstract][Full Text] [Related]
7. Integrin-collagen complex: a metal-glutamate handshake.
Bella J; Berman HM
Structure; 2000 Jun; 8(6):R121-6. PubMed ID: 10873865
[TBL] [Abstract][Full Text] [Related]
8. Identification of critical residues for ligand binding in the integrin beta3 I-domain by site-directed mutagenesis.
Yamanouchi J; Hato T; Tamura T; Fujita S
Thromb Haemost; 2002 Apr; 87(4):756-62. PubMed ID: 12008962
[TBL] [Abstract][Full Text] [Related]
9. Ligand binding results in divalent cation displacement from the alpha 2 beta 1 integrin I domain: evidence from terbium luminescence spectroscopy.
Dickeson SK; Bhattacharyya-Pakrasi M; Mathis NL; Schlesinger PH; Santoro SA
Biochemistry; 1998 Aug; 37(32):11280-8. PubMed ID: 9698375
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18).
Lee JO; Rieu P; Arnaout MA; Liddington R
Cell; 1995 Feb; 80(4):631-8. PubMed ID: 7867070
[TBL] [Abstract][Full Text] [Related]
11. Identification of putative ligand-binding sites of the integrin alpha 4 beta 1 (VLA-4, CD49d/CD29).
Kamata T; Puzon W; Takada Y
Biochem J; 1995 Feb; 305 ( Pt 3)(Pt 3):945-51. PubMed ID: 7531439
[TBL] [Abstract][Full Text] [Related]
12. Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1.
Tidswell M; Pachynski R; Wu SW; Qiu SQ; Dunham E; Cochran N; Briskin MJ; Kilshaw PJ; Lazarovits AI; Andrew DP; Butcher EC; Yednock TA; Erle DJ
J Immunol; 1997 Aug; 159(3):1497-505. PubMed ID: 9233649
[TBL] [Abstract][Full Text] [Related]
13. Mapping functional residues onto integrin crystal structures.
Humphries MJ; Symonds EJ; Mould AP
Curr Opin Struct Biol; 2003 Apr; 13(2):236-43. PubMed ID: 12727518
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of integrin activation by talin.
Wegener KL; Partridge AW; Han J; Pickford AR; Liddington RC; Ginsberg MH; Campbell ID
Cell; 2007 Jan; 128(1):171-82. PubMed ID: 17218263
[TBL] [Abstract][Full Text] [Related]
15. Production of recombinant soluble human integrin alpha4beta1.
Clark K; Newham P; Burrows L; Askari JA; Humphries MJ
FEBS Lett; 2000 Apr; 471(2-3):182-6. PubMed ID: 10767419
[TBL] [Abstract][Full Text] [Related]
16. Structural requirements for mucosal vascular addressin binding to its lymphocyte receptor alpha 4 beta 7. Common themes among integrin-Ig family interactions.
Briskin MJ; Rott L; Butcher EC
J Immunol; 1996 Jan; 156(2):719-26. PubMed ID: 8543825
[TBL] [Abstract][Full Text] [Related]
17. In vitro selection of fibronectin gain-of-function mutations.
Tani PH; Loftus JC; Bowditch RD
Biochem J; 2002 Jul; 365(Pt 1):287-94. PubMed ID: 12071856
[TBL] [Abstract][Full Text] [Related]
18. From crystal clear ligand binding to designer I domains.
Leitinger B; Hogg N
Nat Struct Biol; 2000 Aug; 7(8):614-6. PubMed ID: 10932239
[TBL] [Abstract][Full Text] [Related]
19. The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1.
Lu C; Shimaoka M; Salas A; Springer TA
J Immunol; 2004 Sep; 173(6):3972-8. PubMed ID: 15356146
[TBL] [Abstract][Full Text] [Related]
20. A novel monoclonal antibody recognizing a cation-dependent epitope within the regulatory loop of human beta(1) integrin (CD29).
Lévesque JP; Takada Y; Puzon-McLaughlin W; Simmons PJ
Hybrid Hybridomics; 2002 Aug; 21(4):253-60. PubMed ID: 12193278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
